{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:25:14Z","timestamp":1770722714936,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/cid\/cix486","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T07:09:18Z","timestamp":1495523358000},"page":"1206-1211","source":"Crossref","is-referenced-by-count":15,"title":["Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis"],"prefix":"10.1093","volume":"65","author":[{"given":"David W","family":"Dowdy","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Theron","sequence":"additional","affiliation":[{"name":"DST\/NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Tornheim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Warren","sequence":"additional","affiliation":[{"name":"DST\/NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A","family":"Kendall","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"key\n\t\t\t\t20180328141922_CIT0001","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20180328141922_CIT0002","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180328141922_CIT0003","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0004","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0006","year":"2015"},{"key":"key\n\t\t\t\t20180328141922_CIT0007","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1745-6215-15-353","article-title":"Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial","volume":"15","author":"Nunn","year":"2014","journal-title":"Trials"},{"key":"key\n\t\t\t\t20180328141922_CIT0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/16000617.0080-2015","article-title":"Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials","volume":"25","author":"Moodley","year":"2016","journal-title":"Eur Respir Rev"},{"key":"key\n\t\t\t\t20180328141922_CIT0009","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180328141922_CIT0010","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1093\/infdis\/jir858","article-title":"Drug-resistant tuberculosis\u2014current dilemmas, unanswered questions, challenges, and priority needs","volume":"205","author":"Zumla","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0011","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(16)30729-2","article-title":"WHO recommendations on shorter treatment of multidrug-resistant tuberculosis","volume":"387","author":"Sotgiu","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141922_CIT0012","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1164\/rccm.201605-1080LE","article-title":"Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations","volume":"194","author":"Varaine","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180328141922_CIT0013","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(16)32071-2","article-title":"WHO recommendations for multidrug-resistant tuberculosis","volume":"388","author":"Berry","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141922_CIT0014","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(16)31465-9","article-title":"WHO recommendations for multidrug-resistant tuberculosis\u2014authors\u2019 reply","volume":"388","author":"Sotgiu","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141922_CIT0015","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20180328141922_CIT0016","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.49.9.3977-3979.2005","article-title":"Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model","volume":"49","author":"Ginsburg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328141922_CIT0017","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1086\/598196","article-title":"Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis","volume":"48","author":"Long","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0018","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis\u2014advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0019","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0020","volume-title":"Anti-tuberculosis drug resistance in the world: fourth global report: the World Health Organization\/International Union Against Tuberculosis and Lung Disease global project on anti-tuberculosis drug resistance surveillance, 2002\u20132007","author":"Wright","year":"2008"},{"key":"key\n\t\t\t\t20180328141922_CIT0021","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/antibiotics3030317","article-title":"Drug Resistance Mechanisms in Mycobacterium tuberculosis","volume":"3","author":"Palomino","year":"2014","journal-title":"Antibiotics"},{"key":"key\n\t\t\t\t20180328141922_CIT0022","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1128\/JCM.01257-15","article-title":"Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study","volume":"53","author":"Tagliani","year":"2015","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328141922_CIT0023","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/09031936.05.00111304","article-title":"Drug-susceptibility testing in tuberculosis: methods and reliability of results","volume":"25","author":"Kim","year":"2005","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180328141922_CIT0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/MAJ.0b013e31825d32c6","article-title":"Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing","volume":"345","author":"Kalokhe","year":"2013","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t20180328141922_CIT0025","doi-asserted-by":"crossref","first-page":"MGM2-0023-2013","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol Spectr"},{"key":"key\n\t\t\t\t20180328141922_CIT0026","first-page":"131","article-title":"Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection","volume":"14","author":"Van Deun","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0027","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/JCM.00560-14","article-title":"Diagnostic accuracy of a molecular drug susceptibility testing method for the antituberculosis drug ethambutol: a systematic review and meta-analysis","volume":"52","author":"Cheng","year":"2014","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328141922_CIT0028","doi-asserted-by":"crossref","first-page":"e01819","DOI":"10.1128\/mBio.01819-14","article-title":"Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study","volume":"5","author":"Miotto","year":"2014","journal-title":"MBio"},{"key":"key\n\t\t\t\t20180328141922_CIT0029","first-page":"1","article-title":"An update on repurposed medications for the treatment of drug-resistant tuberculosis","volume":"18","author":"Mafukidze","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328141922_CIT0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Medical Research Council. A Medical Research Council investigation. Streptomycin treatment of pulmonary tuberculosis","volume":"2","year":"1948","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20180328141922_CIT0031","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20180328141922_CIT0032","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199806043382301","article-title":"Global surveillance for antituberculosis-drug resistance, 1994\u20131997. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance","volume":"338","author":"Pablos-M\u00e9ndez","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141922_CIT0033","first-page":"460","article-title":"A controlled trial of six months chemotherapy in pulmonary tuberculosis","volume":"126","author":"British Thoracic Association","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180328141922_CIT0034","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1164\/rccm.201212-2328OC","article-title":"Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis","volume":"188","author":"Ahmad","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180328141922_CIT0035","doi-asserted-by":"crossref","first-page":"e70919","DOI":"10.1371\/journal.pone.0070919","article-title":"Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa","volume":"8","author":"M\u00fcller","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328141922_CIT0036","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180328141922_CIT0037","first-page":"CD010705","article-title":"The diagnostic accuracy of the GenoType(\u00ae) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs","volume":"10","author":"Theron","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180328141922_CIT0038","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/JCM.00251-16","article-title":"Multicenter noninferiority evaluation of hain genotype MTBDRplus version 2 and nipro NTM+MDRTB line probe assays for detection of rifampin and isoniazid resistance","volume":"54","author":"Nathavitharana","year":"2016","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328141922_CIT0039","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1128\/JCM.01179-15","article-title":"Improved detection by next-generation sequencing of pyrazinamide resistance in mycobacterium tuberculosis isolates","volume":"53","author":"Maningi","year":"2015","journal-title":"J Clin Microbiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/7\/1206\/24267229\/cix486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T16:06:41Z","timestamp":1522253201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/65\/7\/1206\/3854941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,5,26]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix486","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,1]]},"published":{"date-parts":[[2017,5,26]]}}}